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Abstract
Macrophages are the special cells of the immune system and play both immu-
nological and physiological role. One of the peculiar characteristics of macro-
phages is that they are double-edged and highly plastic component of immune 
system. Due to this characteristic, they are responsible for both progressions as 
well control of a variety of inflammatory, infectious and metabolic diseases and 
cancer. These are found in the body in three major phenotypes, which are known 
as M0 (also known as naïve); M1 (classically activated macrophages); and/or M2 
(alternatively activated macrophages) at normal physiological conditions. We 
have been exploring macrophages in context of bacterial infection and previ-
ously demonstrated that M2 polarization of M1 effector alveolar macrophages 
during chronic/persistent Chlamydia pneumonia, Mycobacterium tuberculosis and 
Helicobacter pylori pathogens are decisive for the infection induced cancer develop-
ment in host. Since chronic infection with these pathogens has been associated 
with adenocarcinoma, therefore, we feel that disruption of macrophage plasticity 
plays crucial role in the host for the development of cancer. On the basis of this, we 
propose that in such pathological conditions, management of M1/M2 imbalance is 
paramount for minimizing the risk of developing cancer by chronic and persistent 
infection.
Keywords: macrophages, immuno-epigenetics, metabolic programming, 
sterile inflammation, cancer
1. Introduction
Recent studies have demonstrated that macrophages display high grade of 
phenotypic plasticity due to which they can both enhance and inhibit immune 
response. This phenotypical plasticity of macrophages enables them to contribute 
to pathogenesis of large variety of diseases as well as homeostasis mechanisms. 
Due to this characteristic, these cells are now known as double-edge component 
of immunity as well. Many studies have demonstrated that these cells can enhance 
the progression as well as control many infectious and tumor [1] diseases. Both 
peripheral and tissue macrophages together constitute the reticuloendothelium 
system which plays a major role in both sensing microbial antigens and their 
subsequent eradication [2]. Macrophages are recruited to the inflamed/infected 
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tissues, react to a variety of stimuli, and acquire either classical phenotype also 
known as M1 or alternative phenotype also known as (AAM, M2). Classically 
activated macrophages are immunostimulatory in nature and have Th1-orienting 
capacity while M2 are immunoregulatory in nature and have Th2 programming 
capacity [3]. The latter ones are anticipated to support the survival of various 
intracellular pathogens during persistency and believed to promote neoplastic 
transformation of infected tissue micromilieu (Figure 1). AAM accumulation in 
majority of adenocarcinoma (around 10% cases) confers poor prognosis during 
microbial persistency. Therefore in such abnormal pathological conditions, selec-
tive elimination of macrophages by ablating colony-stimulating factor 1(CSF-1) 
in LySMcre and op/op mouse model [4] or by the use of pharmacological drugs 
such as clodronate liposomes [5], which are among few possible modalities for 
mitigating macrophage-associated neoplasia. Within the frame of the above 
mentioned, this chapter will discuss various strategies to repolarize tumor-
associated macrophages (TAM) during cancer development and uncover how 
selective activation of M1 macrophages could control infection-induced cancer 
but also existing anti-tumor immune therapies in both mouse and human model 
of tumors with special emphasis on gastric and lung tumors and inflammatory 
diseases like inflammatory bowel disease (IBD), which are responsible for global 
mortality. This may be achieved by targeting the major intracellular signaling 
component such as sphingolipids and Th2/Th17 responses, which promote M2 
phenotype during persistent infection and potentially involve in the development 
of cancer.
Figure 1. 
Schematic representation of various approaches by which persistent infection with human pathogens disrupts 
functional plasticity of effector macrophages and promote cancer progression. The figure depicts how 
certain pathogens exploit various cellular and genetic mechanisms and promote M2 polarization of iNOS+ 
effector macrophages which are the special and double-edge component of the immune system. Phenotypic 
and functional polarization of effector macrophage is decisive event and anticipated to escort pathogens for 
neoplastic transformation of infected tissues during latent infections.
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2.  Pathogens disrupt macrophage plasticity and effector  
response during persistency
Recent study has demonstrated that a bacterial product known as trabectedin is 
toxic to macrophages. This product inhibits NF-Y and KLF-2/4 which is important 
for the differentiation of macrophages in tumor micromilieu [6]. Similarly mitigat-
ing NF-κB, STAT3 and HIF-1 are involved in the activation of naïve macrophage to 
M1 effector phenotype and hold tremendous therapeutic option for modulating mac-
rophages activation. Histopathological analysis of persistently infected lungs reveals 
the infiltration by specialized macrophage known as foamy macrophages. These are 
lipid-loaded macrophages and quite refractory in their nature. These macrophages 
behave more like AAM and are actively involved in the clearance of cellular debris 
and dead bacteria containing neutrophils and DC [7]. In some cases of coronary 
atheroma patients, these macrophages acquire phenotype similar to TAM (tumor-
associated macrophages) and harbor dead bacteria in their endosome [8]. The pres-
ence of these macrophages thus promotes non-immunogenic inflammation which 
is similar to cancer-associated inflammation and supports opportunistic survival of 
deadly pathogens. Both phenotypic and functional polarizations of M1/M2 effector 
phenotype of macrophages are believed to be one of the prognostic factors contribut-
ing to the development of tumor during persistent/latent infections (Figure 1) in 
host. Once infiltrated in the infected lungs, these AAM/foamy macrophages poten-
tially modify effector T cells and predispose them also as refractory which are other-
wise proficient in the killing of infected cells. These macrophages secrete a plethora 
of cytokines/growth factors like VEGF-β, TGF-β, hypoxia-inducible factor, and 
sphingolipids which altogether contribute to neoplastic transformation of infected 
tissue. High gradient of VEGF and TGF-β promotes the differentiation of regula-
tory T cells [9] and inhibits the effector response of CD8+ T cells [10]. On the other 
hand, sphingolipids particularly S-1P/ceramide (either host or pathogen-derived) 
are known to promote mitophagy [11], M2 polarization of infiltrating M1, or naïve 
monocyte/macrophage populations [12]. In view of this, and to restore Th1 effector 
immune response during latent infection, reactivation of M1 effector phenotype of 
macrophage thus represents the most suitable therapeutic interventions. Apart from 
this, modulating the cytokine network also seems to be the most effective strategy 
for boosting immunity for the management of latent/persistent infections.
3.  Bacterial persistency hijacks programmed cell death and autophagy 
and promotes immune metabolic reprogramming
Pathogenic bacteria have evolved several ways to survive efficiently in the 
phagocytes during their dissemination across the lymphatic system. Various patho-
gens adapt various strategies to this purpose which range from conferring resistance 
to the apoptosis [13], immune evasion [14], and metabolic programming of myeloid 
cells [15] as shown in Figure 2. Of these, conferring resistance and insensitivity for 
cell death in the infected cell seems to be one of the most fundamental processes. 
A range of bacterial pathogens like Chlamydia trachomatis (C. tr), Chlamydia 
pneumonia (C. pn), and Helicobacter pylori (H. pylori) which are associated with the 
pathogenesis of lung [16] and stomach cancer [17] respectively, exploit death and 
immune signaling for surviving in the hostile environment of antigen presenting 
(Figure 2) and effector cells. We [18, 19] and others [20] have demonstrated that 
C. pn and C. tr increase the stability of various endogenous regulators of apoptosis 
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proteins called IAP and inhibit the activity of both apoptotic and inflammatory 
Caspases 3, 8, and 11 during latent infection. Upregulation of CIAP2 and XIAP 
proteins [19] during acute and persistent/latent infection has shown the increase in 
noncanonical signaling of NF-κB which is a master transcription factor involved in 
both cell death inhibition and inflammatory programming and autophagy for Th1 
effector response during infection. Our recent study has shown that C. pneumonia 
potentially interfere with M1 programming of infected macrophages [21] when 
stimulated with their cognate innate and inflammatory stimuli which is due to 
increased expression of HIF-1 and p38MAPK proteins [22] which are known to 
promote unfolded proteins response (UPR) in the infected macrophages [23] which 
in turn predispose macrophages refractory to immune stimulation. Within mac-
rophages, mitochondria is potentially involved in the innate immune response of 
macrophages against a variety of successful intracellular pathogens mainly by flush-
ing catatonic peptides like LL37, CAP 12, and CAP 18 to cytoplasmic compartment 
for efficient capture and killing of pathogen in mature phagolysosomes [24]. Recent 
studies have amply demonstrated that most of the opportunistic pathogens inter-
fere in the mitochondrial physiology by promoting mitophagy which jeopardizes 
innate immune defense of macrophages against pathogens. In such cases, tweaking 
mitochondria by using Smac mimetic-based interventions holds promises in the 
management of persistent infection. Although we have recently demonstrated that 
Smac mimicry [21] is capable of mounting an efficient immune response against 
mild pathogens, it fails to do so against pathogenic microbes like Leishmania 
donovani. Since pathogenic microbes enhance the expression of p38MAPK/HIF-1 
pathways [25] for sabotaging macrophages functions, therefore we feel that at the 
moment targeting p38MAPK/HIF-1 in conjunction to Smac mimetics would be 
paramount for controlling pathogenic microbes. This is a quite intriguing aspect of 
Figure 2. 
Bacterial pathogens potentially exploit and interfere in various pathways in committed macrophage for 
subverting effector mechanisms during latency. Pathogenic bacteria interfere with various key signaling 
pathways which are important for the effector responses, e.g., recognition by receptors, uptake, and phagocytosis, 
lysosomal degradation, and alter signaling pathways and secretion of Th1 cytokines for establishing Th2 bias.
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the field and needs further in-depth investigation. In the same line, many patho-
gens are known to interfere with autophagy process which is yet another potential 
mechanism which influences antigen presentation by APC to T cells for the clear-
ance of pathogens. Many pathogens attack mTORc1 complex and disrupt the 
autophagosome apparatus [26, 27] and inhibit their presentation by APC to T cells 
for immune surveillance during latent phase. Therefore pharmacological tweaking 
of autophagy may offer one potential strategy for clearing dead pathogens effec-
tively from the lung tissue. Irrespective of acute or persistent phase, all pathogens 
utilize host metabolism for their survival inside the host. During persistency, many 
pathogens consume carbohydrate and protein reservoir of infected macrophages 
and alter their metabolic rates. l-Tryptophan [28] and glucose are critical for 
macrophages, and their fluctuation largely dictates the effector response of infected 
macrophages as well as the fate of pathogen in APC/phagocytes. During persistent 
infection, Chlamydia sp. utilize cellular depot of l-tryptophan amino acid by acti-
vating IDO gene and metabolize it to l-kynurenine which impedes glycolysis [29] 
in the macrophages. M1 effector macrophages rely on cellular depot of glucose for 
both activation and differentiation into effector phenotype; therefore, during latent 
infection, pathogens disrupt in the glucose metabolism and promote hypoglycemia 
rendering them refractory for optimum defense against pathogens.
4.  Human pathogens promote epigenetic changes in macrophages  
during persistency
At genome level, C. tr infection causes global hypoacetylation and hypermeth-
ylation of lysine residues on core histones which alter histone post-translational 
modifications which differ between acute and persistent infections. Upregulation of 
pH2AX (Ser139) and H3K9me3 which are hallmarks of DNA double-strand breaks 
(DSBs) and senescence-associated heterochromatin foci (SAHF), respectively, dur-
ing Chlamydophila trachomatis [30] infection suggested teratogenic manifestation 
of Chlamydia persistency. This is largely due to increasing levels of reactive oxygen 
species (ROS) which is produced during latent infection. ROS contribute to DNA 
double-stranded breaks leading to persistent DNA damage, which in turn triggers 
SAHF formation in an ERK-dependent manner [30]. CPAF and CADD proteins 
from Chlamydophila pathogens are known to perturb host cell cycle machinery 
and inhibit recruitment of the DNA damage response proteins pATM and 53BP1 
to damaged sites interfering with DNA repair mechanisms [30]. Despite impaired 
DNA repair, infected cells continue to proliferate which are in turn supported 
by enhanced oncogenic signals such as ERK, CyclinE, and SAHF. These changes 
altogether lead to the malignant transformation of infected tissue. Similarly, other 
pathogens like Campylobacter rectus [31], which is associated with oral cancer, 
downregulate Igf2 gene and enhance DNA methylation at its promoter which can be 
attributed to bacteria-mediated epigenetic modifications to the host genome. Other 
pathogens like Salmonella enterica serovar Typhi, which is one of the prognostic 
factors for the susceptibility for gallbladder carcinoma, exploit MAPK and AKT 
pathways [32] which initiate and sustain neoplastic transformation of infected host. 
Macrophages sense and trigger immune response against pathogens via TLR-linked 
signaling cascade. Under normal circumstance, almost all pathogens trigger TLR 
signaling pathways for activating macrophages; however, only few obligate intracel-
lular pathogens, in hitherto, interfere with TLR signaling directly or indirectly and 
limit defense mechanisms [33] of effector macrophage like pattern of cytokines 
secretions, their uptake, and phagocytosis by macrophages. Although there are mul-
tiple ways how a pathogen can interfere with TLR signaling, so far TLR2/4 triggered 
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hypoxia and associated sterile inflammatory response, and/or TLR masking/
shedding mechanisms have been identified and proposed [34, 35]. Yersinia entero-
colitica and Candida albicans are known to induce immunosuppression through 
TLR2-mediated IL-10 release and differentiation of T-helper cells to CD4+CD25+ 
regulatory T cells [36]. Yersinia species secrete a virulence (V) antigen, LcrV, which 
binds to CD14 and TLR2, trigger IL-10 secretion, and mediate immunosuppression. 
It has recently been shown that a particular residue in the N-terminal region of LcrV 
targets TLR2 and is required for altering IL-10 induction via TLR2 [37]. Likewise, 
H. pylori escapes from recognition by the TLRs due to the removal of phosphate 
groups from the 1′ to 4′ positions of lipid A in LPS, which confers low negative 
charge to this molecule and increases the chance of escaping TLR recognition. The 
recognition of non-LPS ligands by TLR2 leads to anti-inflammatory responses that 
are associated with IL-10 production [38]. Flagellin of H. pylori is one of the PAMP 
which potentially modifies the N-terminal recognition domain of TLR5 and helps 
in escaping the innate immune responses. Manipulation of amino acid 89–96 of 
the recognition domain of TLR5 results in low affinity to flagellin binding [39]. 
Under recurrent/latent infection state, TLR2-mediated signaling, hitherto, inhibits 
IFN-γ response and hijacks Th1 programming of macrophages. A pathogen like M. 
avium inhibits IFN-γ signaling in TLR2-dependent manner where it enhances the 
expression of dominant-negative STAT1b. Similarly, 19KD protein of Mycobacterium 
tuberculosis inhibits IFN-γ-induced expression of HLA-DR and FcγR1 expression on 
human macrophages [40]. In addition to the induction of anti-inflammatory signals 
by TLRs, certain pathogenic microbes have developed strategies to either block or 
avoid their recognition by TLRs and subsequent activation of the innate defense. 
According to one recent study, phospholipids and Ypk protein of Treponema 
pallidum interfere in TLRs (TLR3, TLR4, and TLR9) signaling [41] by blocking 
the function of LPS-binding protein and CD14. Several bacterial pathogens have 
altered specific PAMP structures to circumvent recognition by TLR4 or TLR5; 
pathogens, such as Porphyromonas gingivalis or Leptospira, which have specialized 
LPS structures that only interact with TLR2; likewise, in Helicobacter pylori, the 
flagellin [39, 42] is not appropriately recognized by TLR5, approving the survival 
of the bacteria without loss of virulence. Virulent strains of Salmonella typhi escape 
from their recognition by host PRR by various mechanisms, which predominately 
include modifying their lipid A by various mechanisms including deacylation, 
palmitoylation, and the addition of aminoarabinose [43]. Pathogens have evolved 
in several ways of avoiding NO-mediated killing that plays a central role in effector 
response in phagocytes. Salmonella typhi reside in a specialized membrane compart-
ment called the Salmonella-containing vacuole (SCV), which is similar to inclusion 
in the case of Chlamydia sp. in macrophages, and use a T3SS called Salmonella 
pathogenicity island 2 (Spi2), which protects them from reactive nitrogen inter-
mediates. Spi2-deficient strains of S. typhi get colonized in iNOS+ compartment 
efficiently [44] with the intracellular organisms in the SCV. Intracellular organisms 
have also developed mechanisms to detoxify NO-mediated effects. These include the 
ability to repair damage caused by reactive nitrogen intermediates and to detoxify 
these molecules. Pathogens have evolved the strategies of inhibiting iNOS activity 
which is the characteristic feature of M1 effector macrophages. Mucosal pathogen 
Citrobacterro dentium causes a marked reduction in the level of iNOS activity in 
macrophages [45]. There are many reported examples of bacterial pathogens 
altering inflammatory cytokines related to signaling. Staphylococcus aureus pro-
teins A and M bind directly to the TNF-α receptor 1, on respiratory epithelium, 
which then potentiates a chemokine and cytokine cascade and subsequent disease 
[46]. Similarly, Shigella flexneri, through exploring type III effector, OspG, which 
is a protein kinase, activates ubiquitin-conjugated enzymes, thereby affecting 
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phospho-ikBα degradation and subsequent NF-κB activation. Both Chlamydia 
pneumonia and Chlamydia trachomatis promote shedding of TNF receptor 1 by 
activating TACE activity and shunt TNF signaling though TNFR2 [47] and resist 
antibacterial and inflammatory action of TNF which is major component of effector 
macrophages.
5.  Potential interventions for reactivating refractory macrophages  
for therapy outcome
While the application of antibiotics is sufficient to control acute infection 
however during persistent infection, the outcome of treatment mostly remains 
refractory. This is due to increased density of refractory macrophages in various 
affected tissues which resists many therapies as seen in many similar diseases like 
cancer and metabolic disease which is mediated with tissue accumulation of type 2 
or tumor-associated macrophages. It is now well accepted by medical community 
that increased densities of these macrophages are associated with poor prognosis 
in many infectious, tumor, and metabolic disease. In such conditions antibiotics 
and/or chemotherapy would require an additional regimen for effective treatment. 
During past decades, the growing evidence suggested that TAMs clearly play an 
important role in tumor progression, metastasis, and resistance to available che-
motherapies by modulating the microenvironment inside the tumor mass as well as 
in the stoma. Therefore, it is important to reeducate or target the TAMs (M2-like) 
to antitumor M1-like macrophage phenotype for successful treatment of several 
human malignancies. In the remaining sections of this chapter, we have discussed 
various macrophage-specific and nonspecific interventions for reactivating refrac-
tory population of macrophages for improving existing therapies.
5.1 Neoadjuvant for retuning refractory macrophages
Many interventions have been made to reactivate or retune the TAM, but most of 
them could not influence the disease outcome profoundly. In this context our recent 
studies have shown neoadjuvant impact of low-dose radiation for retuning TAM, 
T cell-aided therapy [48], and subsequent normalization of vasculature in solid 
tumor-bearing animals. Since infection induced adenocarcinoma is manifested with 
high grade infiltration of foamy macrophages, which are like M2 TAM, therefore, on 
the basis of our tumor studies, we propose low dose gamma irradiation as one of the 
non-specific therapeutic interventions for the management of persistent infection-
induced tumor development.
5.2 Nanomedicine as immune adjuvant for refractory macrophages
Nanomedicine has emerged as one of the new modalities for reprogramming of 
both naïve as well as refractory macrophages toward their effector phenotype and 
thus represents one potential intervention for the management of latent infectious 
disease. We and others have recently demonstrated that due to their size and unspe-
cific adjuvant properties, nanocarriers/nanocapsules can penetrate inflamed tissue 
microenvironment effectively and deliver drug in controlled and sustained rate for 
exerting adjuvant actions on macrophages in the inflamed and fibrotic lesions of 
infected tissue. Nanomedicine-based approaches may impact refractory macrophages 
at various levels, namely, (i) enhanced infiltration of fresh monocyte/macrophages, 
(ii) direct killing, and (iii) in situ polarization of AAM/foamy-like macrophages 
during chronic infection to assist clearing of infection. One of the interesting 
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mechanisms by which nanoparticle may improve the therapy outcome is to control 
the differentiation of naive monocytes toward iNOS+ M1 effector macrophages and 
replace CD11b+/iNOS-/Arginase-1+ AAM during chronic infections. In this context, 
our recent work has shown that a certain biodegradable amino acid-based pNAPA 
nanocapsule can potentially stimulate naïve macrophage to the M1 effector pheno-
type. On the basis of these merits, the nanocapsules may be used as adjuvant for acti-
vating innate immune system for the management of infectious diseases and cancer. 
Another potential application of nanoparticles is to deliver drugs or biopharmaceuti-
cals for preventing differentiation of effector phenotype of macrophage to refectory. 
In this context one study has shown that delivery of CCR2 and CCR5 siRNA-loaded 
nanoparticles was able to reduce the recruitment of monocytes to inflamed tissue 
[49]. Nanocarrier-based approaches can be used for the direct killing of the refractory 
macrophages as well. For instance, liposomal formulations have been developed for 
the delivery of bisphosphonates such as zoledronates and clodronates. Subcutaneous/
orthotropic injections of these nanocarriers result in the depletion of AAM accom-
panied with impaired angiogenesis and reduction in metastasis. Nonspecific target-
ing is the major issue with nanocarriers which can be addressed by tagging these 
nanocapsules with specific ligands such as LyP1 and mannose receptors (e.g., CD206) 
which are highly expressed by TAM/AAM [50] for effective targeting of macrophages. 
PLA-PEG nanoparticles, cyclodextrin nanoparticles, and liposomal formulations have 
been developed for loading drug cargoes such as sunitinib, IL-12 plasmids, TGF-β 
inhibitors, and VEGF siRNA for reprogramming of refractory macrophages for skew-
ing in situ Th1 effector immune response against latent infections [51–54].
5.3 Immunotherapeutics are the next-generation treatment modalities
One of the key characteristics of both AAM and TAM is to restrict Th1 immune 
response/T-cell programming by virtue of their releasing of Th2 cytokines and 
growth factors, which stimulate the neoplastic differentiation of inflamed fibroblast 
in tissue [55]. One of the major mechanisms by which these cells limit effector 
T-cell response is to engage programmed cell death ligands 1 and 2 (PD-L1, PD-L2) 
[56] which are expressed by the AAM/TAMs. Pulmonary infiltration of lipid rich 
foamy macrophages is a typical evidence of persistent infection-induced non-
immunogenic/sterile inflammatory immune response during persistent/latent C. 
pn and M. tb infections. Foamy macrophages are special kinds of AAMs which have 
poor antibacterial defense mechanisms and serve as carriers of many pathogens 
during dissemination. These macrophages inhibit Th1 programming of CD4/8+ T 
cells and promote Th2 bias by secreting IL-4 and IL-13 in infected tissue micromilieu 
and help these bacteria in immune escape. These macrophages are known to express 
PD-1L which after binding to PD-1 T cells drives anergy in T cells. Binding of PD-1L 
to PD-1 receptor triggers functional anergy in cytotoxic T lymphocytes (CTL) which 
are otherwise effective in eradicating persistently infected dead cells. Many patho-
gens exploit these pathways as a major immune evasion mechanism for securing 
their opportunistic survival. For example, Chlamydia sp., H. pylori, and Leishmania 
donovani pathogens are known to modulate the expression of PD-L1 on macrophages 
[57–59] for dumping adaptive immune responses. In such conditions, blocking 
PD-L1 pathway by monoclonal antibody against PD-1/PD-L1 has been found to be 
effective in restoring phagocytic potential of macrophages for dead cell clearance 
and subsequent control of tumor in mice models. For this study, it is anticipated that 
co-administration of antibody against PD-1/checkpoint inhibitors (CTLA4) along 
with antibiotics would be beneficial for the management of latent infectious diseases. 
In the same line, vascular endothelial growth factor (VEGF), transforming growth 
factor (TGF-β), fibroblast growth factor (FGF), and platelet-derived growth factor 
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(PDGF), which are potentially secreted by AAM and promote sterile inflammation, 
also represent potential pharmacological targets for enhancing immunogenic death 
of cells during latent phase. Colony-stimulating factor 1 receptor (CSF1R) represents 
yet another promising target for therapeutic interventions because CSF1R signaling 
is crucial for differentiation, recruitment, and survival of TAMs [60].
5.4 Antibody/small molecule inhibitor targeting polarization of refractory 
macrophages
Intracellular pathogens, during both acute and latent infection, fiddle with vari-
ous signaling pathways which range from receptor-associated cell death and innate 
immune signaling, antigen presentation, vesicular transport, and phagocytosis 
pathways. Although we have disused these in earlier section, here we will discuss 
the pharmacological and clinical significance of various approaches which may 
be decisive for mitigating cellular perturbations in the host for restoring immune 
defenses of macrophage during persistency. In this context, our recent study [21] 
has proposed that Smac mimetic (IAP-specific inhibitors)-based strategy has 
potential for enhancing immunogenic cell death of infected cells and reactivating 
refractory macrophages for improved clearance. Due to these virtues, several Smac 
mimetics have entered in the second-phase clinical trial against cancer, and we 
anticipate that the same is expected to help immune system for the management 
of persistent bacterial infection as well. Other than this, many pathogens exploit 
MAPK pathways [61] for their benefits and induce production of IL-10 cytokines in 
the macrophages which further inhibits T-cell programming mainly by promoting 
T-cell exhaustion [62]. Other than this, elevated levels of p38MAPK promote sterile/
anti-inflammatory response, which supports opportunistic survival of pathogen 
inside macrophages. Likewise, many pathogens exploit cAMP/PKA pathways and 
acquire Th2 bias during their persistency [63] for securing their survival; TNF-α 
is a major and key cytokine responsible for receptor-mediated killing of infected 
cells. We (unpublished data) and others have shown that many intracellular patho-
gens, during persistency, potentially target this cytokine and inactivate cell death 
pathways in TACE- or ADAM-dependent manner. Pathogens like Chlamydia sp. 
secrete CPAF, CADD, and hsp60 exerting TACE activity and cause shedding of 
TNFR1 [21], which actually induces cell death. Interestingly these proteins which 
are secreted by chlamydial pathogens require MAPK activation for efficient shed-
ding of TNFR1 [64]. Therefore on the basis of the above observations, designing 
a suitable MAPK/phosphodiesterase 4 (PDE4) inhibitors [65] thus represents a 
compelling approach for controlling bacterial persistency and associated immune 
evade mechanism. Sphingolipids are yet another dual-specific cellular targets [66] 
of many pathogens for deviating Th1 effector immune response [67]. We have 
recently demonstrated that S1P/ceramide rheostat is an important parameter which 
can largely dictate whether pathogen would undergo persistency or not [66]. In this 
direction, we have recently demonstrated that the gain of S-1P during acute M. tb 
infection affords protective immunity in host for controlling pathogen burden; 
however, the same is anticipated to promote mycobacterial persistency and thus in 
such conditions, employment of sphingolipid-based inhibitors, in hitherto, would 
favor host for breaking persistency and induction of protective immune responses.
5.5 Future perspectives: macrophage-based palliative strategies for tissue 
homeostasis post-antibiotic purging
Successful therapy post-antibiotic treatment infection should normalize the tis-
sue microenvironment and restore homeostasis. This could be achieved by chelating 
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oxidative stress and remnants of inflammatory response for the replenishment 
of tissue mass, which normally gets lost during various therapeutic procedures. 
Management of M1/M2 imbalance is believed to be the key for minimizing the risk 
of having cancer by chronic and persistent infection with intracellular pathogens. 
In the clinics, this can be achieved by exchanging refractory populations of macro-
phage with effector ones which can control the sterile reactions and tumorigenesis. 
However, due to the pro-inflammatory nature of iNOS+ effector macrophages, 
this may elicit another sequence of destruction, which alone may not be beneficial. 
Therefore in such delicate conditions, co-administration of M1 macrophage with 
mesenchymal stem cell regenerative approach seems to be optimum for reconstitut-
ing the affected tissues and organs. The potential inclusion of macrophage-mesen-
chymal cell-based therapeutic intervention could be categorized under prospective 
palliative therapies for restoration of physiological function post-treatment.
6. Conclusion
Since chronic infection with bacterial pathogens has been associated with 
adenocarcinoma, therefore, we believe that the management of M1/M2 imbalance is 
paramount for minimizing the risk of developing cancer by chronic and persistent 
infection of the lung, stomach, and cervix. This may be achieved by targeting major 
signaling pathways such as sphingolipids and Th2/Th17 responses which drive M2 
phenotype and which are potentially involved in the development of cancer. In the 
light of the above, we propose that selective activation of M1 macrophages could 
improve existing antitumor immune therapies in both mouse and human models of 
tumors with special emphasis on gastric and lung tumors and inflammatory diseases 
like inflammatory bowel disease (IBD) which are responsible for global mortality.
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Acronyms and abbreviations
MAPK mitogen-activated protein kinase
MAPKK MAPK kinase
MAPKKK MAPKK kinase
NF-κB nuclear factor κB
STAT signal transducer and activator of transcription
TLR toll-like receptor
TNF-α tumor necrosis factor-α
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